Definition of treatment goals for moderate to severe psoriasis: a European consensus

Springer Science and Business Media LLC - Tập 303 Số 1 - Trang 1-10 - 2011
Ulrich Mrowietz1, Knud Kragballe2, Kristian Reich3, Phyllis I. Spuls4, C.E.M. Griffiths5, Alexander Nast6, J Franke1, Christina Antoniou7, Petr Arenberger8, Flora Balieva9, Matilda Bylaitė10, Osvaldo Correia11, E. Daudén12, Paolo Gisondi13, Lars Iversen2, Lajos Kemény14, M. Lahfa15, Tamar Nijsten16, Tapio Rantanen17, Adam Reich18, Thomas Rosenbach19, Siegfried Segaert20, Catherine Smith21, Toomas Talme22, Beatrix Volc‐Platzer23, Nikhil Yawalkar24
1Psoriasis-Center, Department of Dermatology, University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany
2Department of Dermatology, Århus University Hospital, Århus, Denmark
3Dermatologikum Hamburg, Hamburg, Germany
4Department of Dermatology, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
5Dermatology Centre, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK
6Division of Evidence Based Medicine (dEBM), Department of Dermatology, Charité-Universitätsmedizin, Campus Berlin-Mitte, Berlin, Germany
7A. Sygros Hospital, University of Athens Medical School, Athens, Greece
8Department of Dermatology, School of Medicine, Charles University, Prague, Czech Republic
9Department of Dermatology, Stavanger University Hospital, Stavanger, Norway
10Centre of Dermatovenereology, Clinic of Infectious Diseases, Dermatovenereology and Microbiology, Vilnius University, Vilnius, Lithuania
11Centro de Dermatologia Epidermis, Faculty of Medicine, Instituto CUF, Porto, Portugal
12Department of Dermatology, Hospital Universitario La Princesa, Madrid, Spain
13Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy
14Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary
15Hôpital Larrey, Toulouse, France
16Department of Dermatology, Erasmus MC, Rotterdam, the Netherlands
17Department of Dermatology and Allergology, Päijät-Häme Central Hospital, Lahti, Finland
18Department of Dermatology, Venereology and Allergology, Wroclaw Medical University, Wrocław, Poland
19Dermatology Clinic Rosenbach and Partner, Osnabrück, Germany
20Dermatology Department, University Hospital Leuven, Leuven, Belgium
21St John’s Institute of Dermatology, London, UK
22Dermatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
23Department of Dermatology, Sozialmedizinisches Zentrum Ost, Donauspital, Vienna, Austria
24Department of Dermatology, Bern University Hospital, University of Bern, Bern, Switzerland

Tóm tắt

Từ khóa


Tài liệu tham khảo

Augustin M, Krüger K, Radtke MA et al (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216:366–372

Bergman MJ (2009) Assessing adequate treatment response in patients with rheumatoid arthritis. Clin Ther 31:1219–1231

Boehncke WH, Boehncke S, Schön MP (2010) Managing comorbid disease in patients with psoriasis. BMJ 340:b5666

Both H, Essink-Bot ML, Busschbach J, Nijsten T (2007) Critical review of generic and dermatology-specific health-related quality of life instruments. J Invest Dermatol 127:2726–2739

Cohen SB, Cohen MD, Cush JJ et al (2008) Unresolved issues in identifying, overcoming inadequate response in rheumatoid arthritis: weighing the evidence. J Rheumatol Suppl 81:4–30

Dubertret L, Mrowietz U, Ranki A et al (2006) EUROPSO patient survey 2006. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155:729–736

Finlay AY, Khan GK (1994) Dermatology life quality index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19:210–216

Finlay AY (2005) Current severe psoriasis, the rule of tens. Br J Dermatol 152:861–867

Gillard SE, Finlay AY (2005) Current management of psoriasis in the United Kingdom: patterns of prescribing, resource use in primary care. Int J Clin Pract 59:1260–1267

Hasson F, Keeney S, McKenna H (2000) Research guidelines for the Delphi survey technique. J Adv Nurs 32:1008–1015

Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY (2005) Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 125:659–664

Nast A, Kopp I, Augustin M et al (2007) German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 299:111–138

Nast A, Erdmann R, Hofelich V et al (2009) Do guidelines change the way we treat? Studying private practitioners’ prescription behaviour before and after the publication of the German Psoriasis Guidelines. Arch Dermatol Res 301:553–559

Nestle FO, Kaplan DH, Barker JN (2009) Psoriasis. N Engl J Med 361:496–509

Pariser DM, Bagel J, Gelfand JM et al (2007) National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol 143:239–242

Pathirana D, Ormerod AD, Saiag P et al (2009) European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 23(Suppl 2):1–70

Reich K, Nestle FO, Papp K et al (2005) Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 366:1367–1374

Reich K, Mrowietz U (2007) Treatment goals in psoriasis. J Dtsch Dermatol Ges 5:566–574

Reich K, Thaci D, Mrowietz U (2009) Efficacy and safety of fumaric acid esters in the long-term treatment of psoriasis—a retrospective study (FUTURE). J Dtsch Dermatol Ges 7:603–611

Richards HL, Fortune DG, O’Sullivan TM et al (1999) Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 41:581–583

Saurat JH, Stingl G, Dubertret L et al (2008) Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158:558–566

Schoels M, Aletaha D, Smolen JS et al (2010) Follow-up standards and treatment targets in Rheumatoid Arthritis (RA): results of a questionnaire at the EULAR 2008. Ann Rheum Dis 69:575–578

Smith CH, Anstey AV, Barker JN et al (2005) British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 153:486–497

Smith CH, Anstey AV, Barker JN et al (2009) British Association of Dermatologists’ guidelines for biologic interventions for psoriasis. Br J Dermatol 161:987–1019

Spuls PI, Tuut MK, van Everdingen JJ et al (2004) Werkgroep Psoriasis van de Nederlandse Vereniging voor Dermatologie en Venereologie. The practice guideline photo(chemo)therapy and systemic therapy in severe chronic plaque-psoriasis. Ned Tijdschr Geneeskd 148:2121–2125

Spuls PI, Lecluse LL, Poulsen ML et al (2010) How good are clinical severity and outcome measures for psoriasis? Quantitative evaluation in a systematic review. J Invest Dermatol 130:933–943

Storm A, Andersen SE, Benfeldt E, Serup J (2008) One in 3 prescriptions are never redeemed: primary nonadherence in an outpatient clinic. J Am Acad Dermatol 59:27–33

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 303 Số 1

1-10

Thông tin tác giả